Innate Pharma SA IPHA
Innate Pharma SA (Nasdaq: IPHA) is an oncology drug developer. Its lead program, lacutamab (anti-KIR3DL2), is in Phase 2 for cutaneous T-cell lymphoma (Sezary syndrome, mycosis fungoides). Its next catalyst on record is IPH4502: Initial Phase 1 dose-escalation data at ENA 2026 (November 18, 2026).
Upcoming catalysts
- November 18, 2026IPH4502 — Initial Phase 1 dose-escalation data at ENA 2026
Initial Phase 1 dose-escalation data will be presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) on November 18, 2026.
Next further out: monalizumab — PACIFIC-9 Phase 3 readout (AstraZeneca-led) (H2 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| monalizumab (AstraZeneca-sponsored PACIFIC-9) | unresectable Stage III NSCLC | antibody | Phase 3 |
| lacutamab | Sezary syndrome / mycosis fungoides (CTCL); Phase 3 TELLOMAK-3 initiated, first patient not yet dosed | antibody | Phase 2 |
| IPH5201 (anti-CD39, with AstraZeneca) MATISSE | resectable NSCLC | antibody | Phase 2 |
| IPH4502 (Nectin-4 exatecan ADC) | Nectin-4-expressing solid tumors (urothelial, NSCLC, HNSCC) | antibody | Phase 1 |
| Preclinical ADC portfolio | — | antibody | Pre-clinical |
Recent results and decisions
- May 13, 2026positive MATISSE Phase 2 interim (n=40): overall pCR rate 27.5%, 35.7% in PD-L1 >=1% and 50.0% in PD-L1 >=50%; safety comparable to chemo-durvalumab; enrollment continues in PD-L1 >=1%.
The combination showed encouraging results with overall pathological complete response (pCR) rate of 27.5% (95% CI: 14.6–43.9).
Filing - Mar 26, 2026discontinued Phase 1/2 study of IPH6501 in B-NHL discontinued after dose escalation as part of strategic pipeline prioritization; data still expected to be presented in 2026.
Following completion of dose escalation, the study has been discontinued as part of the Company’s strategic prioritization of its pipeline.
Filing - Nov 10, 2025n/a FDA completed review of the confirmatory Phase 3 TELLOMAK 3 protocol with no further comments, clearing the trial to proceed (protocol clearance, not an approval decision).
Food and Drug Administration (FDA) has completed its review of the confirmatory Phase 3 protocol for lacutamab in cutaneous T-cell lymphomas (CTCL), with no further comments, clearing the trial to proceed.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.